{"disease":{"id":"junctional-epidermolysis-bullosa","name":"junctional epidermolysis bullosa"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03269474","title":"Computational Drug Repurposing for All EBS Cases","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Joyce Teng","has_results":false},{"nct_id":"NCT06594393","title":"A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Xinnate AB","has_results":false},{"nct_id":"NCT04727268","title":"Genotype-phenotype Correlation in Junctional Epidermolysis Bullosa","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"University Hospital Birmingham NHS Foundation Trust","has_results":false},{"nct_id":"NCT04908215","title":"INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"InMed Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT03472287","title":"To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Castle Creek Pharmaceuticals, LLC","has_results":true},{"nct_id":"NCT04140786","title":"Optimizing IV Gentamicin in JEB","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":6,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03526159","title":"Gentamicin for Junctional Epidermolysis Bullosa","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03578029","title":"Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Lenus Therapeutics, LLC","has_results":false},{"nct_id":"NCT05111600","title":"Open-label, Pivotal Clinical Trial to Confirm Efficacy and Safety of Autologous Grafts Containing Stem Cells Genetically Modified for Epidermis Restoration in Patients With Junctional Epidermolysis Bullosa","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Holostem s.r.l.","has_results":false},{"nct_id":"NCT03490331","title":"Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With JEB (HOLOGENE17)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Holostem s.r.l.","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}